Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference...
Cancer
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods®Technology Notice of Patent Allowance...
Enliven Therapeutics and Imara Announce Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to...
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1...
ERYTECH Announces Receipt of Nasdaq Notice
ERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq &...
IO Biotech Announces Appointment of New Chief Financial Officer
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers...
CORRECTION — SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- In a release issued today by SOLVE FSHD under the same headline,...
SOLVE FSHD invests US$10 Million in Vita Therapeutics
VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel...
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Data show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above,...
Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
Blindfold run raises $40,000 for the MUHC Foundation to support glaucoma care at the MUHC
Ophthalmologist Dr. Hady Saheb ran 50km while blindfolded to raise awareness and funds for the Glaucoma Service of the McGill...
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19%...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform,...
TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology
Study provides support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE)...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine...